BIOCARTIS GROUP financials
BIOCARTIS GROUP
549300J4HOJL5KG8HY54 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | €47.4M | €57.5M |
| Cost of sales | €20.5M | €29.8M |
| Other income | €303.0K | €495.0K |
| Operating expenses | €89.0M | €105.0M |
| Operating profit (EBIT) | -€41.3M | -€47.0M |
| Net finance income / (cost) | €62.2M | -€17.7M |
| Finance costs | €71.8M | €21.2M |
| Profit before tax | €18.2M | -€65.6M |
| Income tax expense | -€170.0K | -€240.0K |
| Profit for the year | €18.4M | -€65.4M |
| — attributable to owners | €18.4M | -€65.4M |
| Total comprehensive income | €18.3M | -€65.3M |
| Per share | ||
| Basic EPS | €0.20 | €-1.08 |
| Diluted EPS | €0.20 | €-1.08 |
| Cash flow statement | ||
| Cash generated from operations | -€39.6M | -€38.8M |
| Net cash from operating activities | -€47.8M | -€44.9M |
| Income taxes paid | €0 | €2.0K |
| Net cash from investing activities | -€4.8M | -€5.4M |
| Purchase of intangibles | €114.0K | €368.0K |
| Net cash from financing activities | €27.3M | €22.5M |
| Proceeds from borrowings | €53.0M | €15.0M |
| Repayments of borrowings | €62.7M | €26.3M |
| Net change in cash | -€25.4M | -€27.8M |
| Balance sheet | ||
| Total assets | €1.0M | €114.3M |
| Non-current assets | €0 | €44.3M |
| Property, plant & equipment | €0 | €31.5M |
| Current assets | €1.0M | €69.9M |
| Inventories | €0 | €18.9M |
| Trade & other receivables | €18.0K | €16.7M |
| Cash & equivalents | €645.0K | €26.1M |
| Total equity | €721.0K | -€30.3M |
| — attributable to owners | €721.0K | -€30.3M |
| Non-current liabilities | €5.0K | €102.1M |
| Current liabilities | €315.0K | €42.4M |
| Derived metrics | ||
| Operating margin | -87.1% | -81.8% |
| Net margin | 38.8% | -113.7% |
| Return on equity | 2548.8% | 215.9% |
| Cash conversion ratio | -2.60× | 0.69× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | -€831.0K | -€5.8M |
| Adjustments For Decrease Increase In Inventories | -€1.9M | -€5.3M |
| Adjustments For Depreciation and Amortisation Expense | €10.0M | €10.5M |
| Adjustments For Finance Income Cost | -€69.5M | -€17.7M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €2.9M | €1.2M |
| Adjustments For Income Tax Expense | -€170.0K | -€240.0K |
| Adjustments For Increase Decrease In Deferred Income Including Contract Liabilities | -€1.1M | -€791.0K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | -€145.0K | -€143.0K |
| Adjustments For Sharebased Payments | €855.0K | €640.0K |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | -€700.0K | -€884.0K |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | -€7.8M | €0 |
| Comprehensive Income Attributable To Owners of Parent | €18.3M | -€65.3M |
| Current Deferred Income Including Current Contract Liabilities | €0 | €1.2M |
| Deferred Tax Assets | €0 | €1.7M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€104.0K | €426.0K |
| Equity and Liabilities | €1.0M | €114.3M |
| General and Administrative Expense | €15.9M | €16.2M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | -€25.0K | -€114.0K |
| Increase Decrease Through Conversion of Convertible Instruments | €7.2M | €11.0K |
| Increase Decrease Through Sharebased Payment Transactions | €855.0K | €640.0K |
| Intangible Assets Other Than Goodwill | €0 | €4.8M |
| Interest Paid Classified As Financing Activities | €53.0K | €73.0K |
| Interest Paid Classified As Operating Activities | €8.2M | €6.0M |
| Interest Received Classified As Investing Activities | €456.0K | €6.0K |
| Investments In Joint Ventures | €0 | €2.5M |
| Issue of Convertible Instruments | — | €33.1M |
| Issued Capital | -€220.3M | -€220.3M |
| Noncurrent Deferred Income Including Noncurrent Contract Liabilities | €0 | €149.0K |
| Noncurrent Financial Assets | €0 | €3.6M |
| Noncurrent Provisions | €5.0K | €204.0K |
| Other Adjustments To Reconcile Profit Loss | -€167.0K | -€78.0K |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | €0 | €1.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€86.0K | -€385.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€6.0K | €378.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€59.0K | -€271.0K |
| Other Current Assets | €0 | €6.0M |
| Other Current Liabilities | €21.0K | €8.9M |
| Other Current Receivables | €378.0K | €2.2M |
| Other Finance Income Cost | €2.3M | €3.5M |
| Other Noncurrent Assets | €0 | €204.0K |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €2.5M | €0 |
| Purchase of Financial Instruments Classified As Investing Activities | €0 | €2.5M |
| Research and Development Expense | €32.5M | €38.4M |
| Reserve of Sharebased Payments | €8.4M | €7.5M |
| Restricted Cash and Cash Equivalents | — | €1.2M |
| Retained Earnings | -€425.7M | -€443.4M |
| Revenue and Operating Income | €47.7M | €58.0M |
| Revenue From Rendering of Services | €1.9M | €1.4M |
| Revenue From Sale of Goods | €36.4M | €45.0M |
| Sales and Marketing Expense | €20.1M | €20.6M |
| Share of Profit Loss of Joint Ventures Accounted For Using Equity Method | -€700.0K | -€884.0K |
| Share Premium | €639.2M | €631.7M |
| Trade and Other Current Payables To Trade Suppliers | €294.0K | €11.7M |
Every line item above is a fact tagged in BIOCARTIS GROUP's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.